![AstraZeneca / MedImmune / Business / Venture capital / TRPV / Transient receptor potential channel / Pfizer / Ion channels / Membrane biology / Biology AstraZeneca / MedImmune / Business / Venture capital / TRPV / Transient receptor potential channel / Pfizer / Ion channels / Membrane biology / Biology](https://www.pdfsearch.io/img/5e9629e7b0d0654e34a953e3784ea54f.jpg)
| Document Date: 2009-01-21 17:10:08 Open Document File Size: 77,95 KBShare Result on Facebook
City San Francisco / Brisbane / Palo Alto / New York / Atlanta / Cambridge / Alameda / / Company Singulex Inc. / Hydra Biosciences Inc. / BrainCells Inc. / J.P. Morgan / MedImmune Ventures / Anacor Pharmaceuticals Inc. / Lilly Ventures / Biogen Idec Ventures / Pfizer Inc. / Aisling Capital / Londonbased AstraZeneca plc / BiPar Sciences Inc. / AHC Media LLC / LigoCyte Inc. / AstraZeneca / Advanced Technology Ventures / / Country United States / Canada / / Currency USD / / Event Funding / Employment Change / / IndustryTerm venture capital / noncannabinoid product / platform technology / venture capital front / / Organization National Venture Capital Assoc. / / Person Russell Herndon / Karen GottingSmith / Maggie Flanagan LeFlore / / / Position Jennifer Boggs Assistant Managing Editor Financial experts / president and CEO / managing director / board member / / Product Series D / / ProvinceOrState California / Georgia / Massachusetts / / Technology high-throughput screening / platform technology / / URL www.bioworld.com / /
SocialTag |